Sotrastaurin

DB12369InvestigationalSmall molecule

Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.

Mechanism: Pharmacologically active on Protein kinase C
Curator reviewed
Formula / weight: C₂₅H₂₂N₆O₂ · 438.4812 g/mol (avg)
Code names: AEB071

Resolves to

Compound

UNII7I279E1NZ8CAS425637-18-9ChEMBLCHEMBL565612ChEBI90531PubChem10296883

Structure

InChIKeyOAVGBZOFDPFGPJ-UHFFFAOYSA-NSMILESCN1CCN(CC1)C1=NC(C2=C(C(=O)NC2=O)C2=CNC3=C2C=CC=C3)=C2C=CC=CC2=N1

Targets

P17252PRKCAP05771PRKCBQ04759PRKCQ

What you can answer from here — as of September 19, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

17Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sotrastaurin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account